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We have reported that excretory/secretory (ES) products from Spirometra erinaceieuropaei
plerocercoids suppress production and gene expression of tumor necrosis factor (TNF)-α
in murine macrophages stimulated with lipopolysaccharide.  The present study demon-
strates that ES products suppress TNF-α, interleukin (IL)-1β and intercellular adhesion
molecule (ICAM)-1 gene expression in human monocytic leukemia cell line THP-1 stimu-
lated with Plasmodium falciparum-cultured medium (Pf-CM).  Inhibition of extracellular-
signal regulated protein kinase 1/2 (ERK1/2) with PD98059 reduced TNF-α, IL-1β and
ICAM-1 gene expression; on the contrary inhibition of p38 mitogen-activated protein kinase
(MAPK) with SB203580 increased the expression of these genes.  These findings indicated
that ERK1/2, but not p38 MAPK pathway is important for induction of TNF-α, IL-1β and
ICAM-1 gene expression in Pf-CM stimulated THP-1 monocytes.  ES products additionally
suppress IL-1β, but not TNF-α and ICAM-1 gene expression in Pf-CM stimulated THP-1
cells treated with PD98059.  We hypothesize that ES products may be useful in reducing
falciparum malaria-induced inflammatory response and sequestration in the late stage of
malarial diseases such as cerebral malaria.
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Plasmodium falciparum malaria is the most promi-
nent parasitic infection in humans.  It has been
known that the pathogenesis of Plasmodium falci-
parum malaria depends on many factors, including
the destruction of erythrocytes, drug resistance,
cytoadherence and immunological responses (Clark
et al., 1989; Aikawa et al., 1990).  In malaria,
although complement and antibody-mediated im-
mune responses are important (Rigione et al., 1996;
Guevara et al., 1997; Kumaratilake et al., 1997),
cell-mediated immunity is also involved in the pro-
tection and pathogenesis of this disease and some
reports suggest that the host immunological re-
sponses, especially those mediated through the
cytokine cascade, may determine the severity of
malaria (Artavanis and Riley, 2002).  Severe falci-
Abbreviations:  dNTPs, deoxyribonucleotide triphosphate; ERK1/2, extracellular-signal regulated protein kinase 1/2;
ES, excretory/secretory; ICAM, intercellular adhesion molecule; IL, interleukin; LPS, lipopolisaccharide; MAPK,
mitogen-activated protein kinase; M-MLV RT, Moloney mouse leukemia virus reverse transcriptase; Pf-CM,
Plasmodium falciparum-cultured medium; PMA, phorbol 12-myristate-13 acetate; RT, reverse transcription; TNF,
tumor necrosis factor
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parum malaria is usually accompanied by serious
secondary complication, such as cerebral malaria,
severe anemia, hypoglycemia and renal impairment
(Aikawa et al., 1990; Kwiatkowski, 1990).  Several
lines of evidences implicate that tumor necrosis fac-
tor (TNF)-α is a major mediator for these complica-
tions.  Indeed, it has been reported there is an eleva-
tion in serum levels of not only TNF-α, but also inter-
leukin (IL)-1β and IL-6 in patients with falciparum
malaria (Kwiatkowski et al., 1989, 1990; Kwiatkowski,
1990), which are correlated with severity of the
disease and death (Grau et al., 1989; Clark et al.,
1990; Kwiatkowski et al., 1990; Kurtzhals et al.,
1998).  A study by Udomsangpetch et al. (1997) show-
ed that there were localized high levels of inflam-
matory cytokines TNF-α, IL-1β and interferon-γ in
the brain tissue of a patient who died from cerebral
malaria, in which an up-regulation of adhesion
molecules such as CD36 or intercellular adhesion
molecule (ICAM)-1 and sequestration of parasit-
ized erythrocytes, lymphocytes and monocytes to
the endothelial cells were associated.  Identification
of ICAM-1 as a major sequestration receptor, espe-
cially in the brain, has led to the assumption that it
contributes to the pathophysiology of severe malar-
ia (Aikawa et al., 1990).  In fact, in the early stages
of malaria, the mild and moderate amount of in-
flammatory cytokines, such as TNF-α or IL-1β, are
beneficial for the host by suppressing and killing
the parasite (Grau et al., 1989; Clark et al., 1990;
Kwiatkowski, 1990; Kwiatkowski, et al., 1990).
However, in later stages, an excessive production of
these cytokines are detrimental, since activation of
phagocytes to kill intracellular or extracellular
parasites requires a great amount of inflammatory
cytokine production which can cause adverse sys-
temic effects such as severe anemia and cerebral
malaria (Kwiatkowski, 1990; McGuire et al., 1994;
Luty et al., 2000).
The plerocercoids of Spirometra erinaceieu-
ropaei, one species of parasitic tapeworm, has been
known to produce anti-inflammatory like sub-
stance(s) which suppressed the nitrite production
and gene expression of inducible nitric oxide syn-
thase (Fukumoto et al., 1997) and the TNF-α in
murine macrophages stimulated with lipopolysac-
charide (LPS) (Miura et al., 2001; Dirgahayu et al.,
2002).  Based on these findings and on what we
now understand about malaria pathogenesis, the
present study was conducted to investigate whether
excretory/secretory (ES) products from these plero-
cercoids might suppress TNF-α, IL-1β and ICAM-
1 mRNA expression of the human monocytic leuke-
mia cell line THP-1 induced by Plasmodium falci-
parum-cultured medium (Pf-CM).  A possible po-
tential role of ES products in malaria pathogenesis
will be discussed.
Materials and Methods
Plerocercoids of Spirometra erinaceieuro-
paei and their ES products
Plerocercoids of Spirometra erinaceieuropaei were
collected from 2 species of snakes (Elaphe quadri-
virgata and Rhabdophis tigrinus) in the southern
part of Ehime Prefecture, Japan and stored for over
6 months in the subcutaneous tissues of golden ham-
sters, which were housed and maintained according
to the guidelines for proper treatment of animals at
the Division of Laboratory Animal Science, Research
Center for Bioscience and Technology, Tottori Uni-
versity, Japan.  ES products were obtained as de-
scribed previously (Miura et al., 2001).  The protein
concentration was assayed using a Bio-Rad protein
assay kit (Bio-Rad, Hercules, CA) and adjusted to 50
µg/mL.  We made separate lots for ES products
from each golden hamster in order to perform sev-
eral experiments independently.  One representa-
tive experiment is shown here.
Preparation of Pf-CM
The Pf-CM was obtained from the continuous cul-
ture of Plasmodium falciparum FCR-3 strain which
was maintained according to the method of Trager
and Jensen (1976), kindly provided by the Depart-
ment of Molecular Parasitology, School of Medicine,
Ehime University, Japan.  The Pf-CM was obtained
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from the culture when the parasite reached an initial
hematocrit of 5% in RPMI 1640 medium (Sigma
Chemical, St. Louis, MO) supplemented with HEPES
buffer (25 mM) and 0.2% NaHCO3 with 10% heat-
inactivated human serum (albumax) (Gibco BRL,
Paisley, United Kingdom).  The cultured-medium
were then treated as previously described (Ballet et
al., 1981; Abdalla and Wickramasinghe, 1985).  Brief-
ly, 40 mL of Pf-CM (20% parasitemia) was centri-
fuged for 3000 rpm for 20 min at 4˚C prior to dia-
lyzation against cold distilled water for 48 h.  After
being lyophilized, the sample was then re-suspend-
ed in 4 mL RPMI 1640.  The Pf-CM was then pass-
ed through a 0.45-µm-pore-size membrane filter
and stored at –30˚C until use.  Thawed media were
filtered again through a 0.45-µm-pore-size mem-
brane filter before being added to culture.
Cell culture
The human monocytic leukemia cell line THP-1
(TIB-202) was purchased from RIKEN cell bank
(Tokyo, Japan).  THP-1 cells were grown in RPMI
1640 medium supplemented with 10% fetal bovine
serum (Gibco BRL, Gaithersburg, MD) containing
100 U/mL penicillin G (Banyu Pharmaceutical,
Tokyo) and 100 µg/mL streptomycin (Meiji Seika.,
Tokyo), plated in tissue culture dishes (Greiner,
Frickenhausen, Germany), and incubated at 37˚C in
an atmosphere of 5% CO2 in a humidified incuba-
tor.  We differentiated the THP-1 cells by re-suspend-
ing them for 24 h in medium containing 200 nM of
phorbol 12-myristate-13-acetate (PMA) (Wako,
Tokyo), as previously described by Reyes et al.
(1999).  Such treatment with PMA induces the con-
version of THP-1 into mature cells as macrophages
(Tsuchiya et al., 1980), designated “THP-1-derived
macrophages”.  The macrophages were washed
with phosphate buffered saline and were left over-
night before treatment.  We used polymyxin B (10
µg/mL) (Sigma Chemical) for treatment of ES prod-
ucts for all subsequent experiments prior to stimula-
tion with Pf-CM.
Reverse transcription (RT)-PCR analysis
Total RNA was prepared from Pf-CM-stimulated or
control macrophages using an ISOGEN Kit (Nippon
Gene, Tokyo) according to the manufacturer’s proto-
col.  Approximately 1 µg of total RNA was reverse-
transcribed in a 20 µL reaction volume according to
the manufacturer’s protocol.  Approximately 1 µg
of total RNA was reverse-transcribed in a 20 µL re-
action volume consisting of 2.5 µL random hex-
amers (50 pM), 4 µL 5× Moloney mouse leukemia
virus reverse transcriptase (M-MLV RT)-reaction
buffer, 2.5 µL deoxyribonucleotide triphosphate
(dNTPs) (2.5 mM each) (Nippon Gene, Tokyo), 1 µL
of RNase-inhibitor and 1 µL of M-MLV RT en-
zyme (all reagents were purchased from Promega,
Tokyo).  PCR reactions were run on a Perkin Elmer
DNA Thermal Cycler (Takara, Kyoto, Japan), in 20
µL total volume per reaction mixture containing 2
µL of cDNA RT products, 1.6 µL dNTPs mix (2.5
mM each), 2 µL 10× Gene Taq Universal buffer
(Nippon Gene, Tokyo), 1 µL of each primer (diluted
to 20 µM) and 0.1 µL Taq Gold.  Primer sequences
used were as follows: TNF-α: (sense: 5'-AAG CCT
GTA GCC CAT GTT GT-3' and antisense: 5'-CAG
ATA GAT GGG CTC ATA CC-3'), ICAM-1:
(sense: 5'-AAT GCC CAG ACA TCT GTG TC-3'
and antisense: 5'-CAG TTC AGT GCG GCA CGA
GAA AT-3'), IL-1β: (sense: 5'-GCT CCT TCC
AGG ACC TGG AC-3' and antisense: 5'-CGT
GCA CAT AAG CCT CGT TA-3') and β-actin:
(sense: 5'-CCA GAG CAA GAG AGG CAT CC-3'
and antisense: 5'-GTG GTG GTG AAG CTG TAG
CC-3').  The PCR cycles consisted of denaturation
at 94˚C for 30 s, annealing at 60˚C for 1 min and
extension at 72˚C for 1 min for 27 cycles (TNF-α),
25 cycles (ICAM-1), 23 cycles (IL-1β) and 21 cy-
cles (β-actin) for semi-quantitative analysis.  A 15
µL aliquot of each of the PCR products was sepa-
rated by electrophoresis on a 1.5% agarose gel,
stained with ethidium bromide and photographed.
For quantification, photographs showing PCR prod-
ucts were scanned and analyzed using Densitograph
version 4.0 software (ATTO, Tokyo).  For each sam-
ple, the PCR product values were normalized to the
β-actin PCR product values.
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Results
Induction of TNF-α, IL-1β and ICAM-1 mRNA
expressions of THP-1 cells in response to
Pf-CM
We first examined the effect of Pf-CM on the induc-
tion of TNF-α, IL-1β and ICAM-1 mRNA expres-
Fig. 1.  TNF-α, IL-1β and ICAM-1 gene expressions in
human monocytes stimulated with LPS or Pf-CM.  THP-
1 monocytes were left unstimulated or stimulated with
LPS (100 ng/mL), Pf-CM or heat-inactivated human se-
rum (HS) for 4 h in the absence or presence of poly-
myxin B (10 µg/mL).  Total RNA (1 µg/lane) was ob-
tained and the levels of TNF-α, ICAM-1, IL-1β and β-
actin mRNA expression were assessed by semiquanti-
tative RT-PCR.  One representative of 3 experiments is
shown.  PoB, polymyxin B.
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Fig. 2.  Effect of ES products on the Pf-CM-induced
TNF-α, IL-1β and ICAM-1 gene expression in human
monocytes.  THP-1 monocytes were left untreated or
pretreated with ES products (5 µg/mL) and polymyxin B
(10 µg/mL) for 6 h, washed, and then the medium was
replaced before the stimulation with 250 µL of Pf-CM or
human serum (HS) for 4 h.  Total RNA (1 µg/lane) was
obtained and the levels of TNF-α, ICAM-1, IL-1β and β-
actin mRNA was analyzed by semiquantitative RT-PCR.
One representative of 3 experiments is shown.
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sions.  As seen in Fig. 1, Pf-CM induced TNF-α,
IL-1β and ICAM-1 mRNA accumulation in THP-1
cells (lane 4).  Although LPS-induced gene expres-
sion of TNF-α, IL-1β and ICAM-1 mRNA was re-
duced in the presence of polymyxin B (lane 3), Pf-
CM-induced expression of these genes was not pre-
vented in the presence of polymyxin B (lane 5).  No
appreciable band was observed in controls and hu-
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Fig. 3.  MAPK inhibitors differentially modulate the Pf-
CM-induced TNF-α, IL-1β and ICAM-1 mRNA expres-
sions in THP-1 monocytes.  THP-1 monocytes were pre-
treated with 5 µg/mL ES products and 10 µg/mL of poly-
myxin B for 6 h.  The cells were then washed and the
medium was replaced.  The cells were then either treated
with PD98059 (50 µM), SB20358, (10 µM) or a combi-
nation of these inhibitors for 1 h prior to the stimulation
with 250 µL Pf-CM for an additional 3 h incubation.
Total RNA (1 µg/lane) was obtained and TNF-α, ICAM-
1 and β-actin mRNA was assessed by semiquantitative
RT-PCR.  One representative of 3 experiments is shown.
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man serum-treated monocytes in the absence of
LPS or Pf-CM (lanes 1 and 6).  These results indi-
cate that Pf-CM has the ability of some stimulatory
activity to induce the gene expression of pro-inflam-
matory cytokines and ICAM-1, and this activity ex-
hibited in Pf-CM-cultured THP-1-cells is a Plasmo-
dium falciparum origin, without a trace of endo-
toxin contamination.
Treatment of THP-1 cells with ES products
prior to stimulation with Pf-CM prevent induc-
tion of TNF-α, IL-1β and ICAM-1 gene expres-
sion
In order to evaluate the impact of ES products on
TNF-α, IL-1β and ICAM-1 gene expressions of
THP-1 cells, these monocytes were left untreated or
treated with 5 µg/mL ES products and polymyxin B
prior to stimulation with 250 µL Pf-CM in the final
medium volume of 3 mL.  As shown in Fig. 2, ES
products potently reduced TNF-α mRNA (by 76%),
IL-1β (by 85%) and ICAM-1 mRNA expression (by
60%) in response to Pf-CM (lane 3).  THP-1 cells
treated with human serum showed a band pattern
similar to the controls (lanes 1 and 5).  The levels of
constitutively expressed β-actin mRNA, however,
did not change with the treatment of ES products.
This result shows that ES products are a potent in-
hibitor for TNF-α, IL-1β and ICAM-1 gene expres-
sion in human monocytes in response to Pf-CM.
Role of ERK1/2 and p38 MAPK pathways in
the induction of TNF-α, IL-1β and ICAM-1
gene expression in Pf-CM-stimulated THP-1
cells
Using well-known pharmacological inhibitors of
the ERK1/2 and p38 MAPK pathways, PD98059
and SB203580, respectively (Dudley et al., 1995),
we investigated the suppressive mechanisms of ES
products on TNF-α, IL-1β and ICAM-1 gene ex-
pressions in human monocytes stimulated with Pf-
CM.  THP-1 cells were pretreated with 5 µg/mL ES
products and polymyxin B for 6 h, washed and then
the medium was replaced.  The monocytes were
then treated with SB203580 and/or PD98059 for 1 h
before the addition of 250 µL Pf-CM in the final vol-
ume of 3 mL for further 3 h incubation.  As shown in
Fig. 3, PD98059 treatment suppressed TNF-α, IL-
1β and ICAM-1 mRNA expression by 83%, 75%
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and 73% (lane 6), respectively; however, SB203580
treatment induced approximately 1.5-fold levels of
the TNF-α, IL-1β mRNA and ICAM-1 mRNA ex-
pression (lane 4), compared to the positive controls
(lane 2).  Combination of PD98059 and SB203580
profoundly reduced the 3 genes to near control lev-
els (lane 8).  These data indicate that the ERK1/2
MAPK pathway, but not p38 MAPK is important
for induction of TNF-α, IL-1β and ICAM-1 mRNA
expression in THP-1 cells stimulated with Pf-CM.
We observed an additional suppressive effect by ES
products on IL-1β, but not TNF-α, and ICAM-1
mRNA expression in the cells treated with PD98059
(lane 7).
Discussion
A complex parasite such as human Plasmodium is
likely to generate a variety of substances that injure
the hosts directly or cause immunopathology.  It has
been widely known that severe malaria is associat-
ed with a failure of the host defense system to con-
trol parasite replication, excessive secretion of pro-
inflammatory cytokines and sequestration of para-
sitized-erythrocytes in vital organs, such as the kid-
ney, the lungs, the brain, etc.  The excessive secre-
tion of pro-inflammatory cytokines, such as TNF-α,
IL-1β and IL-6 (Aikawa et al., 1990) has been as-
sumed because of the stimulation of effector cells by
certain parasite-derived toxins [substance(s)], re-
leased by ruptured schizonts that cause paroxysms
of fever.  This substance(s) has been shown to con-
tain glycosylphosphatidylinositol (Schofield and
Hacket, 1993; Schofield et al., 1996; Tachado et al.,
1996) and malarial pigments (Pichyangkul et al.,
1994).  Several studies have shown that glycosyl-
phosphatidylinositol anchor, a membrane attach-
ment mechanism for cell surface proteins widely
used in eukaryotes, plays a crucial role in the pa-
thology of malaria by inducing pro-inflammatory
cytokines, including iNOS (Schofield et al., 1996;
Tachado et al., 1996), TNF-α (Schofield et al., 1993)
and ICAM-1 (Schofield et al., 1996).  Pichyangkul et
al. (1994) demonstrated that sequestered malaria pig-
ment in the microvasculature also induced production
and induction of TNF-α and IL-1β gene expression
of murine macrophages.  In agreement with several
previous studies (Abdalla and Wickramasinghe, 1985;
Taverne et al., 1990a, 1990b), we demonstrated that
Pf-CM induced TNF-α, IL-1β and ICAM-1 mRNA
expression in THP-1 cells, which was not abolished
by the treatment of 10 µg/mL polymyxin B (Fig. 1),
suggesting that the stimulatory activity of Pf-CM
was of parasite origin.  We found that pretreatment
of THP-1 monocytes with ES products prior to
stimulation by Pf-CM reduced TNF-α, IL-1β and
ICAM-1 gene expression (Fig. 2).  We are confident
that the results are not a consequence of toxicity
since treatment of macrophages by ES products for
over 24 h neither inhibited the growth of cell num-
bers (unpublished data) nor affected the expression
level of the house-keeping gene β-actin.
Further investigation through the MAPK path-
way showed that pretreatment of THP-1 cells with
PD98059 partially inhibited TNF-α, IL-1β and
ICAM-1 mRNA expression, whereas SB203580,
instead of inhibition, induced all gene expressions
approximately 1.5 times compared to the positive
controls (Fig. 3) and a combination of PD98059 and
SB203580 profoundly reduced TNF-α, IL-1β and
ICAM-1 mRNA expression to near control levels,
indicating that the ERK1/2 pathway is important for
optimal induction of TNF-α, IL-1β and ICAM-1
mRNA expression.  We observed that ES products
additionally suppress IL-1β mRNA expression in
LPS-stimulated THP-1 cells treated with PD98059,
suggesting that ES products may suppress IL-1β
mRNA by inhibiting phosphorylation of the ERK1/2
pathway.  The reason for this additional suppressive
effect only observed for IL-1β mRNA expression is
still unclear.
Paroxysmal fever is the hallmark of malaria.
Several observations indicate that TNF-α is a criti-
cal mediator of malarial fever:  i) it is a potent endoge-
nous pyrogen (Dinarello et al., 1986); ii) when P.
falciparum is cultured with human monocytes, the
rate of TNF production rises sharply at the time of
schizont rupture (Kwiatkowski, 1990; Kwiatkowski et
al., 1990); iii) in P. vivax  infection, paroxysmal fever
is associated with a sharp rise in circulating TNF
levels (Karunaweera et al., 1992) and iv) anti-TNF
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therapy inhibits fever in children with cerebral ma-
laria (Kwiatkowski et al., 1993).  However, TNF-α
is not the only mediator of malaria fever.  Other
cytokines also have pyrogenic properties, including
IL-1β (Rocket et al., 1994), IL-1α (Kwiatkowski et
al., 1990) and IL-6 (Kern et al., 1989), which are
produced mainly by the monocytes/macrophages
series.  In addition to the pyrogenic effect, TNF-α,
has been shown to induce ICAM-1 gene expression
of the endothelial cell, the major adherence receptor
in the brain (Aikawa et al., 1990; Udomsangpetch et
al., 1997).  A study by Udomsangpetch et al. (2002)
demonstrated that febrile temperatures in the range
usually encountered during malaria induced cyto-
adherence of the ring-stage of Plasmodium falci-
parum-infected erythrocytes in vitro.  This fever-
induced cytoadherence was shown to be associated
with increased expression of the Plasmodium falci-
parum-erythrocyte membrane protein-1, a protein
which is exported from the parasite and linked to
the erythrocyte cytoskeleton during the 2nd half of
the life cycle, on the surface of the infected red
blood cell (Sharma, 1991).  Up-regulating ICAM-1
expression of the endothelial cells allows parasites
to bind and sequester in cerebral vessels, disrupting
the function of the central nervous system (Adams
et al., 2000), and in turn, leading to cerebral malar-
ia.  Based on the understanding of the pathogenesis
of malaria, we suppose that suppression of TNF-α
and IL-1β mRNA expression in THP-1 cells by ES
products would, in turn, reduce the expression of
ICAM-1 of endothelial cells by decreasing fever in-
directly.  In addition, ES products might also directly
suppress ICAM-1 expression in monocytes.
In epidemic areas, helminthic infections com-
monly coexist with malaria in an individual.  The
significance of such concurrent infection, however,
is not yet clearly understood.  However, results
have revealed that worm infection is associated
with protection from cerebral malaria (Nacher et
al., 2000), acute renal failure and jaundice (Nacher
et al., 2001).  Thus, worms might be central to natu-
ral anti-malarial immunity.  Worms, which can in-
duce a bias towards Th-2 cytokines and depress
other cytokines could render the host more suscep-
tible to liver-stage parasites and favor P. falciparum
reproduction but protect the host from severe com-
plication of blood stage malaria.  The beneficial or
detrimental role of TNF-α, IL-1β and ICAM-1 dur-
ing malaria attack could have important conse-
quences, and modulation of these mediators during
acute disease could lead to a novel approach in the
treatment of malaria.  Although co-infection of ma-
laria and Spirometra erinaceieuropaei is unusual,
the evidence presented here points to the possibility
that ES products might be useful in reducing in-
flammatory responses and the phenomenon of se-
questration in severe malaria, especially in cerebral
malaria.
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